| Literature DB >> 29354010 |
Atsushi Nambu1,2, Jordan Zach1, Song Soo Kim1,3, Gongyoung Jin1,4, Joyce Schroeder1,5, Yu-Il Kim6,7, Russell Bowler8, David A Lynch1.
Abstract
Objective: To assess clinical feasibility of low-attenuation cluster analysis in evaluation of chronic obstructive pulmonary disease (COPD). Materials andEntities:
Keywords: COPD; CT; Chronic obstructive pulmonary disease; Cluster size analysis; Low attenuation area; Quantitative CT
Mesh:
Year: 2018 PMID: 29354010 PMCID: PMC5768494 DOI: 10.3348/kjr.2018.19.1.139
Source DB: PubMed Journal: Korean J Radiol ISSN: 1229-6929 Impact factor: 3.500
Fig. 13D cluster analysis in patient with severe emphysema.
In this rendering, 3D-connected low-attenuation voxels are represented by sphere with volume corresponding to that of real cluster that has more complex shape. 3D = three-dimensional
Patient Characteristics (n = 199) and Measurements of Physiological Examinations and Quantitative CT
| Mean ± SD (Range) | |
|---|---|
| Age (years) | 64.1 ± 8.40 (45 – 80) |
| Sex (male:female) | 100:99 |
| Body mass index | 27.69 ± 5.59 (16.33 – 44.97) |
| Smoking pack years | 50.86 ± 23.86 (10.50 – 150.00) |
| GOLD stage 0:I:II:III:IV | 15:11:72:66:35 |
| %FEV1* | 51.27 ± 23.10 (15 – 150) |
| FEV1/FVC* | 0.47 ± 0.15 (0.18 – 0.89) |
| DLCO/VA (mL/min/mm Hg/L) | 2.67 ± 1.06 (0.66 – 6.17) |
| LAA% | 16.10 ± 12.92 (0.08 – 58.55) |
| 2D D value−950HU | −1.807 ± 0.339 (−2.70 – −1.12) |
| 3D D value−950HU | −1.525 ± 0.185 (−1.98 – −1.08) |
| 2D D value−910HU | −1.394 ± 0.275 (−2.43 – −0.91) |
| 3D D value−910HU | −1.585 ± 0.184 (−1.91 – −1.17) |
| 2D D value−856HU | −0.912 ± 0.256 (−1.60 – −0.39) |
| 3D D value−856HU | −1.501 ± 0.177 (−1.90 – −0.89) |
*%FEV1 and FEV1/FVC were measured after inhalation of bronchodilator. DLCO = diffusion capacity for carbon monoxide, FEV = forced expiratory volume, FVC = forced vital capacity, GOLD = global initiative for chronic obstructive pulmonary disease, LAA% = percentages of low attenuation areas ≤ −950 Hounsfield unit in CT value, VA = alveolar volume, 2D = two-dimensional, 3D = three-dimensional, 2D and 3D D value = slopes of functions of cluster sizes and cumulative frequencies that were calculated two-dimensionally and three-dimensionally, respectively, on log-log scale, %FEV1 = percentage of predicted forced expiratory volume at one second (see text for details)
Correlation Coefficients (p value) between Quantitative CT Measurements (D values of Cluster Analyses and %LAA−950HU), and Clinical Metrics and Physiological Measurements in All Subjects (n = 199)
| 2D D value−950HU | 3D D value−950HU | 2D D value−910HU | 3D D value−910HU | LAA% | |
|---|---|---|---|---|---|
| Age | 0.061 (0.389) | 0.120 (0.091) | 0.096 (0.180) | 0.060 (0.401) | 0.037 (0.600) |
| Sex | 0.038 (0.598) | 0.110 (0.121) | −0.169 (0.017) | 0.123 (0.083) | −0.145 (0.042) |
| Body mass index | −0.560 (< 0.001) | −0.541 (< 0.001) | −0.504 (< 0.001) | −0.551 (< 0.001) | −0.464 (< 0.001) |
| Smoking pack years | −0.038 (0.596) | −0.022 (0.761) | 0.028 (0.696) | −0.039 (0.586) | −0.016 (0.818) |
| GOLD stage | 0.413 (< 0.001) | 0.247 (0.001) | 0.415 (< 0.001) | 0.339 (< 0.001) | 0.553 (< 0.001) |
| %FEV1 | −0.400 (< 0.001) | −0.271 (< 0.001) | −0.430 (< 0.001) | −0.364 (< 0.001) | −0.549 (< 0.001) |
| FEV1/FVC | −0.534 (< 0.001) | −0.396 (< 0.001) | −0.610 (< 0.001) | −0.460 (< 0.001) | −0.667 (< 0.001) |
| DLCO/VA | −0.587 (< 0.001) | −0.559 (< 0.001) | −0.605 (< 0.001) | −0.628 (< 0.001) | −0.646 (< 0.001) |
| LAA% | 0.796 (< 0.001) | 0.516 (< 0.001) | −0.718 (< 0.001) | 0.620 (< 0.001) |
Correlation Coefficients (p value) between Quantitative CT Measurements (D values of Cluster Analyses and %LAA−950HU), and Clinical Metrics and Physiological Measurements in Subjects with Mild COPD (GOLD Stage 0–II, n = 98)
| 2D D value−950HU | 3D D value−950HU | 2D D value−910HU | 3D D value−910HU | LAA% | |
|---|---|---|---|---|---|
| Age | 0.168 (0.098) | 0.322 (0.001) | 0.105 (0.305) | 0.277 (0.006) | 0.217 (0.032) |
| Sex | 0.197 (0.051) | 0.231 (0.022) | −0.143 (0.161) | 0.205 (0.042) | −0.108 (0.290) |
| Body mass index | −0.375 (< 0.001) | −0.440 (< 0.001) | −0.363 (< 0.001) | −0.448 (< 0.001) | −0.238 (0.018) |
| Smoking pack years | 0.066 (0.518) | 0.103 (0.314) | 0.203 (0.045) | 0.039 (0.704) | 0.177 (0.081) |
| GOLD stage | 0.128 (0.211) | 0.133 (0.191) | 0.353 (< 0.001) | 0.182 (0.074) | 0.410 (< 0.001) |
| %FEV1 | −0.196 (0.053) | −0.167 (0.100) | −0.350 (< 0.001) | −0.225 (0.026) | −0.343 (0.001) |
| FEV1/FVC | −0.394 (< 0.001) | −0.322 (0.001) | −0.598 (< 0.001) | −0.353 (< 0.001) | −0.615 (< 0.001) |
| DLCO/VA | −0.509 (< 0.001) | −0.625 (< 0.001) | −0.555 (< 0.001) | −0.652 (< 0.001) | −0.617 (< 0.001) |
| LAA% | 0.655 (< 0.001) | 0.410 (< 0.001) | 0.707 (< 0.001) | 0.458 (< 0.001) |
COPD = chronic obstructive pulmonary disease
Fig. 2Scatter plots showing relationships between %FEV1 and LAA%, and %FEV1 and 2D D value−910HU.
A. %FEV1 vs. LAA% in subjects. B. %FEV1 and 2D D value−910HU in subjects. C. %FEV1 vs. LAA% in subjects with mild emphysema. D. %FEV1 vs. 2D D value−910HU in subjects with mild emphysema. Note that dots are more scattered in areas with lower LAA% in (A) and (C) and that dots are closer to regression line in subjects with mild emphysema (D) than in all subjects (B). LAA% = percentages of low attenuation areas ≤ −950 Hounsfield unit in CT value, 2D = two-dimensional, 2D D value = slopes of functions of cluster sizes and cumulative frequencies that were calculated two-dimensionally, on log-log scale, %FEV1 = percentage of predicted forced expiratory volume at one second
Results of Fisher's Z Tests
| 2D D Value−950HU vs. LAA% | 3D D Value−950HU vs. LAA% | 2D D Value−910HU vs. LAA% | 3D D Value−910HU vs. LAA% | ||
|---|---|---|---|---|---|
| All subjects (n = 199) | %FEV1 | 0.080 | 0.002* | 0.168 | 0.030* |
| DLCO/VA | 0.327 | 0.168 | 0.490 | 0.772 | |
| Subjects with mild COPD (n = 98) | %FEV1 | 0.337 | 0.242 | 0.897 | 0.453 |
| DLCO/VA | 0.271 | 0.897 | 0.535 | 0.631 |
Comparison of correlation coefficients between each D value and physiological measurements, and between LAA% and physiological measurements. p values of corresponding physiological measurements are shown in intersection cells. *p values less than 0.05 (considered significant).
Multivariable Analyses for FEV1% and DLCO/VA in All Subjects (n = 199)
| %FEV1 (Adjusted R2 = 0.303) | DLCO/VA (Adjusted R2 = 0.520) | |
|---|---|---|
| Sex | 0.017 (0.782) | −0.048 (0.360) |
| Body mass index | −0.142 (0.045) | 0.051 (0.398) |
| Age | 0.047 (0.441) | −0.177 (< 0.001) |
| LAA% | −0.524 (< 0.001) | −0.424 (< 0.001) |
| 2D D value−910HU | −0.126 (0.163) | |
| 3D D value−910HU | −0.320 (< 0.001) |
Numbers in cells are standardized β values (p value). D value that had highest correlation coefficients with %FEV1 and DLCO/VA was used in each regression model.
Multivariable Analyses for FEV1% and DLCO/VA in Subjects with Mild COPD (GOLD Stage 0–II, n = 98)
| %FEV1 (Adjusted R2 = 0.119) | DLCO/VA (Adjusted R2 = 0.555) | |
|---|---|---|
| Sex | −0.020 (0.838) | < 0.001 (0.997) |
| Body mass index | −0.159 (0.129) | 0.044 (0.377) |
| Age | −0.029 (0.772) | −0.170 (0.022) |
| LAA% | −0.173 (0.214) | −0.381 (< 0.001) |
| 2D D value−910HU | −0.286 (0.050) | |
| 3D D value−910HU | −0.410 (< 0.001) |
Numbers in cells are standardized β values (p value). D value that had highest correlation coefficients with %FEV1 and DLCO/VA was used in each regression model.